Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion

Eli Lilly to acquire obesity drug maker Versanis for .9 billion


Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Cristina Arias | Cover | Getty Images

Eli Lilly on Friday said it will acquire Versanis, a privately held obesity drug maker, for up to $1.93 billion to boost the pharmaceutical giant’s weight loss treatment portfolio. 

Eli Lilly agreed to pay Versanis shareholders in cash, which will consist of an upfront payment and potentially subsequent payments if Versanis achieves certain “development and sales milestones.”

Oakland, California-based Versanis, which was founded in 2021 by biotech investment firm Aditum Bio, has one experimental drug for obesity and potentially other conditions.

Eli Lilly’s stock price rose 3% on Friday following the announcement.

The deal is Eli Lilly’s latest attempt to capitalize on the weight loss industry gold rush, which began last year after Novo Nordisk’s blockbuster injections Wegovy and Ozempic boomed in popularity. 

An estimated 40% of U.S. adults are obese. Analysts project that the global weight loss drug market could be worth $100 billion by around 2030. 

Versanis’s drug, bimagreumab, binds directly to certain cells in the body to reduce fat mass.

The company is studying bimagreumab in a phase two trial in adults who are overweight or obese, and in another trial that compares the treatment with Novo Nordisk’s Wegovy and Ozempic.

Bimagreumab works differently from Novo Nordisk’s drugs and similar treatments from Indianapolis-based Eli Lilly. Those drugs, known as GLP-1 agonists, mimic hormones produced in the gut called incretins to suppress a person’s appetite.

But Versanis said combining bimagreumab with those incretin-based therapies could potentially lead to better outcomes for people living with obesity and cardiometabolic conditions, which includes diabetes, kidney disease and disorders affecting the heart. 

CNBC Health & Science

Read CNBC’s latest health coverage:

Eli Lilly is working on several obesity treatments. 

The company’s once-weekly experimental injection, retatrutide, helped overweight or obese patients lose up to 24% of their weight after 48 weeks.

That surpasses the weight reduction caused by other obesity drugs.

Eli Lilly’s experimental obesity pill, orforglipron, also helpd overweight or obese patients lose up to 14.7% of their body weight after 36 weeks.

The company is also pushing to approve its type 2 diabetes treatment, Mounjaro, for obesity. 



Source

Healthy Returns: Researchers move closer to a universal cancer vaccine
Health

Healthy Returns: Researchers move closer to a universal cancer vaccine

Wildpixel | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality.  On […]

Read More
U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 
Health

U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., speaks with Agriculture Secretary Brooke Rollins and Senator Roger Marshall (R-KS) ahead of a roundtable event as part of the “Make America Healthy Again” (MAHA) agenda, on Capitol Hill in Washington, D.C., U.S., July 15, 2025. Ken Cedeno | Reuters The Department of Health […]

Read More
FDA taps biotech industry veteran as RFK Jr.’s top drug regulator 
Health

FDA taps biotech industry veteran as RFK Jr.’s top drug regulator 

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009.  Jason Reed | Reuters The Food and Drug Administration said on Monday it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator. Tidmarsh, an adjunct professor of pediatrics and neonatology […]

Read More